跳至主要内容
临床试验/NCT06981754
NCT06981754已完成不适用

Intravenous Dexamethasone Palmitate for Prophylaxis of Postoperative Nausea and Vomiting After Minimally Invasive Endoscopic Surgery

Beijing Tiantan Hospital2 个研究点 分布在 1 个国家目标入组 588 人开始时间: 2025年6月17日最近更新:
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
588
试验地点
2
主要终点
The incidence of PONV

研究概览

简要总结

Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, 14.0-26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adverse effects. This trial aims to assess the effect and safety of preoperative dexamethasone palmitate on PONV after surgery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 18 to 65 years;
  • Providing written informed consent;
  • Patients scheduled to undergo elective minimally invasive endoscopic surgery (laparoscopic or thoracoscopic surgery) under general anaesthesia.

排除标准

  • Known to be allergic to dexamethasone;
  • Any systemic glucocorticoids within 3 months before trial entry;
  • History of severe heart disease, liver/kidney failure, or systemic rheumatic diseases (rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, et al);
  • Cognitive impairment or severe mental illness;
  • Uncontrolled diabetes or infectious diseases;
  • Pregnancy or breastfeeding.

研究组 & 干预措施

Dexamethasone palmitate group

Experimental

干预措施: Dexamethasone palmitate (Drug)

Dexamethasone group

Active Comparator

干预措施: Dexamethasone (Drug)

结局指标

主要结局

The incidence of PONV

时间窗: Within the first 24 hours postoperatively

PONV will be defined as any nausea, emetic episodes (vomiting or retching), or both. Nausea is defined as an unpleasant sensation with an urge to vomit. Vomiting is defined as the physical event of forcefully expelling gastric contents through the mouth. Retching refers to the forced movement of gastrointestinal contents without actual expulsion of vomitus.

次要结局

  • The Incidence of PONV(At 6 hours, 48 hours, and 72 hours postoperatively)
  • Incidence of postoperative nausea (PON) and postoperative vomiting (POV)(At 6 hours, 24 hours, 48 hours, and 72 hours postoperatively)
  • The number of vomiting or retching episodes(Within 6 hours, 24 hours, 48 hours, and 72 hours postoperatively)
  • The severity of PONV(At 6 hours, 24 hours, 48 hours, and 72 hours postoperatively)
  • Participant satisfaction with PONV management(At 6 hours, 24 hours, 48 hours, and 72 hours postoperatively)
  • The use of rescue antiemetic drugs(During the 0-24 hours, 24-48 hours, and 48-72 hours postoperatively)
  • The quality of postoperative recovery (QoR)(At 24 and 48 hours postoperatively, discharge, and 1 month postoperatively)
  • The VAS scale(At 6 hours, 24 hours, 48 hours, and 72 hours postoperatively)
  • Postoperative length of stay (LOS)(At discharge)
  • Safety outcomes(Throughout the entire research period)

研究者

发起方
Beijing Tiantan Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Fang Luo

Beijing Tiantan Hospital, Capital Medical University

Beijing Tiantan Hospital

研究点 (2)

Loading locations...

相似试验